Disease · MONDO_0005928
post-thrombotic syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. post-thrombotic syndrome. Diseases, record MONDO_0005928. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005928
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| COLCHICINE | CHEMBL107 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIOSMIN | CHEMBL231884 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ALTEPLASE | CHEMBL1201593 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Unknown | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DABIGATRAN | CHEMBL48361 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EDOXABAN | CHEMBL1269025 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENOXAPARIN | CHEMBL1201685 | Oligosaccharide | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HEPARIN SODIUM | CHEMBL1201657 | Oligosaccharide | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 20
See all 20 targetsTrials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00082355 | Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins | Phase 2 | 30 | 2012-12-19 | Acute Deep Venous Thrombosis of the Lower Extremity | ALTEPLASE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01999179 | Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis | Not applicable | 27 | 2021-12-22 | Venous Thrombosis, Neoplasms | APIXABAN, DABIGATRAN, EDOXABAN, ENOXAPARIN, RIVAROXABAN | Its record names the disease | ClinicalTrials.gov |
| NCT07432529 | Design and Rationale of the COLT Study | Phase 3 | 940 | Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE), Venous Insufficiency | COLCHICINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05701917 | DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis | Not applicable | 300 | Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome | APIXABAN, HEPARIN SODIUM, RIVAROXABAN, WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02704598 | Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. | Not applicable | 84 | Deep Venous Thrombosis | RIVAROXABAN, WARFARIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005928
GET https://conductscience.org/api/diseases/v1/MONDO_0005928/drugs